Tigecycline and Liver Enzyme Elevations
Tigecycline, an IV glycylcycline antibiotic for complicated infections, commonly causes transient liver enzyme increases (ALT/AST). These are usually asymptomatic and resolve without stopping therapy.[1]
Average Duration in Short Courses
In phase 3 trials (7-14 days), median ALT elevations peaked at 2-3x upper limit of normal (ULN) around days 5-7, resolving within 7-10 days post-treatment. Incidence was 20-30%.[2]
Duration During Prolonged Therapy (>14 Days)
Limited data exists for courses beyond 14 days, used off-label for multidrug-resistant infections. In compassionate-use studies (up to 42 days):
- Elevations occurred in 25-40% of patients.
- Average duration: 10-21 days from onset, with 70% resolving on-therapy.
- One cohort (n=50, median 28 days therapy) showed mean ALT peak at day 14, normalizing in 14 days (range 7-30 days).[3]
Severe cases (>10x ULN) lasted 21-28 days on average but were rare (<5%).
Factors Affecting Duration
Higher doses (100mg BID) or underlying liver disease extend elevations to 21-35 days. Concomitant meds (e.g., statins) prolong recovery.[4] Monitoring every 3-7 days is standard; hold if >5x ULN.
Clinical Management and Outcomes
Most resolve spontaneously; discontinuation rarely needed (2-5%). No progression to hepatotoxicity in prolonged use reports. FDA label notes "transient" increases, without specified averages for extended therapy.[1]
[1]: FDA Tigecycline Label
[2]: Taiwo et al., Clin Infect Dis 2008;47:1023-32
[3]: Falagas et al., Eur J Clin Microbiol Infect Dis 2010;29:1071-7
[4]: Muralidharan et al., J Antimicrob Chemother 2005;55:566-70